Literature DB >> 10648433

Localizing value of epileptic visual auras.

C G Bien1, F O Benninger, H Urbach, J Schramm, M Kurthen, C E Elger.   

Abstract

It is difficult to differentiate between seizures of occipital or temporal lobe origin in patients with focal epileptic seizures associated with visual aura. These are often suspected to originate from the visual cortex, which causes reluctance to propose resection as treatment for the affected patient. To determine the value of localizing different types of visual auras, we report on 20 patients experiencing visual aura from a series of 878 surgically treated patients suffering from intractable focal seizures. In all of these patients, a morphological abnormality was identified on MRI (n = 18) or cranial CT (n = 2). These abnormalities were shown to represent the morphological correlate of the epileptogenic zone in each case, as demonstrated by intracranial ictal EEG recordings and/or seizure freedom after focal resective surgery. Elementary hallucinations, illusions and visual loss were reported not only by all patients with occipital lobe epilepsy, but also by patients with occipitotemporal and anteromedial temporal seizure onset. Complex hallucinations never occurred in occipital lobe seizures but were present in the two other groups. The same correlation was found for concentric changes of visual field (tunnel vision), a newly described ictal phenomenon. We conclude that elementary hallucinations, illusions and visual loss, although typical for occipital lobe epilepsy, can also occur in anteromedial temporal or occipitotemporal seizures and are therefore not a discordant feature in presurgical evaluation of patients with suspected temporal lobe epilepsy. Complex hallucinations and tunnel vision, however, should be considered concordant only with the assumption of an anteromedial temporal or occipitotemporal seizure onset.

Entities:  

Mesh:

Year:  2000        PMID: 10648433     DOI: 10.1093/brain/123.2.244

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  19 in total

1.  Nonlesional atypical mesial temporal epilepsy: electroclinical and intracranial EEG findings.

Authors:  Kanjana Unnwongse; Andreas V Alexopoulos; Robyn M Busch; Tim Wehner; Dileep Nair; William E Bingaman; Imad M Najm
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

2.  New insights in the limbic modulation of visual inputs: the role of the inferior longitudinal fasciculus and the Li-Am bundle.

Authors:  Francesco Latini
Journal:  Neurosurg Rev       Date:  2014-10-17       Impact factor: 3.042

3.  Charles Bonnet syndrome successfully treated with levetiracetam.

Authors:  Thomas Grüter; Ilya Ayzenberg; Ralf Gold; Christian Börnke
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

Review 4.  Visual hallucinations and the Charles Bonnet syndrome.

Authors:  Dominic H Ffytche
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

Review 5.  Imaging of the epilepsies.

Authors:  H Urbach
Journal:  Eur Radiol       Date:  2005-01-28       Impact factor: 5.315

6.  Severe presentation of antibody-negative, postinfectious steroid-responsive encephalitis and atonic bladder after herpes simplex encephalitis.

Authors:  Luay Mrad; Argirios Moustakas; Robert Fuino; Waqar Waheed
Journal:  BMJ Case Rep       Date:  2019-07-22

7.  Visual Hallucinations.

Authors:  Victoria S. Pelak; Grant T. Liu
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

8.  Multiple auras: not an ominous sign for epilepsy surgery.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2008 Mar-Apr       Impact factor: 7.500

9.  Visual command hallucinations in a patient with pure alexia.

Authors:  D H Ffytche; J M Lappin; M Philpot
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

10.  Epilepsy partialis continua with visual allesthesia.

Authors:  Mario F Mendez; James W Y Chen
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.